Topical Olopatadine in the Treatment of Allergic Conjunctivitis: A Systematic Review and Meta-analysis. (3rd September 2017)

• Record Type: Journal Article
• Authors: Kam, Ka Wai; Chen, Li Jia; Wat, Noel; Young, Alvin L.
• Is Part Of: Ocular immunology and inflammation. Volume 25:Number 5(2017)
• Page Start: 668
• Page End: 682
• Publication Date: 2017-09-03
• Subjects: Allergic conjunctivitis -- antihistamine -- cornea and external eye -- mast cell stabilizer -- meta-analysis -- olopatadine; Eye -- Diseases -- Immunological aspects -- Periodicals; Eye -- Inflammation -- Periodicals; 617.7
• DOI: 10.3109/09273948.2016.1158282
• Languages: English
• ISSNs: 0927-3948

Abstract

ABSTRACT: Purpose : To assess the safety and efficacy of topical olopatadine versus placebo and other topical anti-allergic medications in treating allergic conjunctivitis. Methods : We systematically searched the literature for randomized-controlled trials that included patients with allergic conjunctivitis, compared olopatadine versus placebo or alternative anti-allergic medications, and examined itch, conjunctival hyperemia, composite symptom or sign scores, and/or occurrence of adverse events. We assessed the safety and efficacy of topical olopatadine when compared with placebo or alternative anti-allergic medications using meta-analysis. Results : When compared with placebo, topical olopatadine is associated with a pooled-mean difference (MD) in ocular itch of –1.33 ( p < 0.00001) and ocular hyperemia of –0.92 ( p < 0.00001). When compared with other agents, olopatadine was inferior to alcaftadine on ocular itch (pooled-MD = 0.39; p < 0.00001) but comparable with epinastine and ketotifen. Conclusions : Topical olopatadine is a safe and effective treatment modality for allergic conjunctivitis, whereas alcaftadine appears to be superior to olopatadine in reducing ocular itch.